"Our findings suggest serelaxin holds promise as the first evidence-based therapy for acute heart failure to substantially improve patients' symptoms and clinical outcomes, including death, said Teerlink, who is director of the heart failure program at the San Francisco Veterans Affairs Medical Center." . . . .